PEG-PLA from PolySciTech used in development of Monoclonal antibody labeled nanoparticles for targeted delivery.

 

The ability to direct and target nanoparticles towards desired cells or tissues is a powerful therapeutic technique which can address many disease states. This is not a trivial task in the human body for many reasons including rapid clearance of particles from the bloodstream by organs such as the liver or kidneys as well as immune attack against the particles. Recently, researchers at Yale University and New York University PEG-PLA (cat# AK054), PLA-PEG-COOH (cat# AI030), PLA-PEG-mal (cat# AI065) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to development broadly applicable Mab targeted nanoparticles and tested these for perfusion models. This research holds promise to improve targeted nano-therapies in the future. Read More: C. Albert, L. Bracaglia, A. Koide, J. DiRito, T. Lysyy, L. Harkins, C. Edwards, O. Richfield, J. Grundler, K. Zhou, E. Denbaum, G. Ketavarapu, T. Hattori, S. Perincheri, J. Langford, A. Feizi, D. Haakinson, S. A. Hosgood, M. L. Nicholson, J. S. Pober, W. M. Saltzman, S. Koide, G. T. Tietjen “Monobody adapter for functional antibody display on nanoparticles for adaptable targeted delivery applications” Nature Communications volume 13, Article number: 5998 (2022) https://www.nature.com/articles/s41467-022-33490-8

“Abstract: Vascular endothelial cells (ECs) play a central role in the pathophysiology of many diseases. The use of targeted nanoparticles (NPs) to deliver therapeutics to ECs could dramatically improve efficacy by providing elevated and sustained intracellular drug levels. However, achieving sufficient levels of NP targeting in human settings remains elusive. Here, we overcome this barrier by engineering a monobody adapter that presents antibodies on the NP surface in a manner that fully preserves their antigen-binding function. This system improves targeting efficacy in cultured ECs under flow by >1000-fold over conventional antibody immobilization using amine coupling and enables robust delivery of NPs to the ECs of human kidneys undergoing ex vivo perfusion, a clinical setting used for organ transplant. Our monobody adapter also enables a simple plug-and-play capacity that facilitates the evaluation of a diverse array of targeted NPs. This technology has the potential to simplify and possibly accelerate both the development and clinical translation of EC-targeted nanomedicines.”